Concurrent chemoradiotherapy by simultaneously integrated boost volumetric-modulated arc therapy for nasopharyngeal carcinoma-toxicity/quality of life and survival

Fu Min Fang; Tai Lin Huang; Yun Hsuan Lin; Chih Yen Chien; Hui Ching Chuang; Sheng Dean Luo; Hsin Ching Lin; Yu Tsai Lin; Shau Hsuan Li; Kuan Cho Liao; Wen Ling Tsai

doi:10.1002/hed.25551

Concurrent chemoradiotherapy by simultaneously integrated boost volumetric-modulated arc therapy for nasopharyngeal carcinoma-toxicity/quality of life and survival

Fu Min Fang^*, Tai Lin Huang, Yun Hsuan Lin, Chih Yen Chien, Hui Ching Chuang, Sheng Dean Luo, Hsin Ching Lin, Yu Tsai Lin, Shau Hsuan Li, Kuan Cho Liao, Wen Ling Tsai

^*Corresponding author for this work

Research output: Contribution to journal › Journal Article › peer-review

8 Scopus citations

Abstract

Background: To investigate the toxicity, changes of quality of life (QOL), and survival for patients with nasopharyngeal cancer (NPC) treated by concurrent chemoradiotherapy (CCRT) with simultaneously integrated boost volumetric-modulated arc therapy (SIB-VMAT). Methods: A total of 68 NPC patients treated by CCRT with SIB-VMAT technique were collected. QOL was longitudinally assessed by the EORTC QLQ-C30 and HN35 questionnaires at the 4 time points: baseline, 42.4 Gy (20 fractions), and 3, 12 months after CCRT. Results: The 4-year locoregional relapse free, distant metastasis free, failure free, and overall survival rates were 97.0%, 86.4%, 82.0%, and 88.1%, respectively. The 4-year cumulative incidence rate of late toxicities with grade 3 or more was 3.0%. One year after CCRT, most QOL scales, except some oral related symptoms, recovered to baseline level. Conclusion: CCRT with SIB-VMAT produces excellent locoregional control, few severe late toxicity, and good general health status for NPC patients.

Original language	English
Pages (from-to)	1282-1289
Number of pages	8
Journal	Head and Neck
Volume	41
Issue number	5
DOIs	https://doi.org/10.1002/hed.25551
State	Published - 05 2019

Bibliographical note

Publisher Copyright:
© 2018 Wiley Periodicals, Inc.

Keywords

concurrent chemoradiotherapy
nasopharyngeal carcinoma
quality of life
simultaneously integrated boost
volumetric-modulated arc therapy

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/hed.25551

Cite this

Fang, F. M., Huang, T. L., Lin, Y. H., Chien, C. Y., Chuang, H. C., Luo, S. D., Lin, H. C., Lin, Y. T., Li, S. H., Liao, K. C., & Tsai, W. L. (2019). Concurrent chemoradiotherapy by simultaneously integrated boost volumetric-modulated arc therapy for nasopharyngeal carcinoma-toxicity/quality of life and survival. Head and Neck, 41(5), 1282-1289. https://doi.org/10.1002/hed.25551

@article{06b8cb96dffc44798be50772a22d4b21,

title = "Concurrent chemoradiotherapy by simultaneously integrated boost volumetric-modulated arc therapy for nasopharyngeal carcinoma-toxicity/quality of life and survival",

abstract = "Background: To investigate the toxicity, changes of quality of life (QOL), and survival for patients with nasopharyngeal cancer (NPC) treated by concurrent chemoradiotherapy (CCRT) with simultaneously integrated boost volumetric-modulated arc therapy (SIB-VMAT). Methods: A total of 68 NPC patients treated by CCRT with SIB-VMAT technique were collected. QOL was longitudinally assessed by the EORTC QLQ-C30 and HN35 questionnaires at the 4 time points: baseline, 42.4 Gy (20 fractions), and 3, 12 months after CCRT. Results: The 4-year locoregional relapse free, distant metastasis free, failure free, and overall survival rates were 97.0%, 86.4%, 82.0%, and 88.1%, respectively. The 4-year cumulative incidence rate of late toxicities with grade 3 or more was 3.0%. One year after CCRT, most QOL scales, except some oral related symptoms, recovered to baseline level. Conclusion: CCRT with SIB-VMAT produces excellent locoregional control, few severe late toxicity, and good general health status for NPC patients.",

keywords = "concurrent chemoradiotherapy, nasopharyngeal carcinoma, quality of life, simultaneously integrated boost, volumetric-modulated arc therapy",

author = "Fang, {Fu Min} and Huang, {Tai Lin} and Lin, {Yun Hsuan} and Chien, {Chih Yen} and Chuang, {Hui Ching} and Luo, {Sheng Dean} and Lin, {Hsin Ching} and Lin, {Yu Tsai} and Li, {Shau Hsuan} and Liao, {Kuan Cho} and Tsai, {Wen Ling}",

note = "Publisher Copyright: {\textcopyright} 2018 Wiley Periodicals, Inc.",

year = "2019",

month = may,

doi = "10.1002/hed.25551",

language = "英语",

volume = "41",

pages = "1282--1289",

journal = "Head and Neck",

issn = "1043-3074",

publisher = "John Wiley & Sons Inc.",

number = "5",

}

TY - JOUR

T1 - Concurrent chemoradiotherapy by simultaneously integrated boost volumetric-modulated arc therapy for nasopharyngeal carcinoma-toxicity/quality of life and survival

AU - Fang, Fu Min

AU - Huang, Tai Lin

AU - Lin, Yun Hsuan

AU - Chien, Chih Yen

AU - Chuang, Hui Ching

AU - Luo, Sheng Dean

AU - Lin, Hsin Ching

AU - Lin, Yu Tsai

AU - Li, Shau Hsuan

AU - Liao, Kuan Cho

AU - Tsai, Wen Ling

PY - 2019/5

Y1 - 2019/5

N2 - Background: To investigate the toxicity, changes of quality of life (QOL), and survival for patients with nasopharyngeal cancer (NPC) treated by concurrent chemoradiotherapy (CCRT) with simultaneously integrated boost volumetric-modulated arc therapy (SIB-VMAT). Methods: A total of 68 NPC patients treated by CCRT with SIB-VMAT technique were collected. QOL was longitudinally assessed by the EORTC QLQ-C30 and HN35 questionnaires at the 4 time points: baseline, 42.4 Gy (20 fractions), and 3, 12 months after CCRT. Results: The 4-year locoregional relapse free, distant metastasis free, failure free, and overall survival rates were 97.0%, 86.4%, 82.0%, and 88.1%, respectively. The 4-year cumulative incidence rate of late toxicities with grade 3 or more was 3.0%. One year after CCRT, most QOL scales, except some oral related symptoms, recovered to baseline level. Conclusion: CCRT with SIB-VMAT produces excellent locoregional control, few severe late toxicity, and good general health status for NPC patients.

AB - Background: To investigate the toxicity, changes of quality of life (QOL), and survival for patients with nasopharyngeal cancer (NPC) treated by concurrent chemoradiotherapy (CCRT) with simultaneously integrated boost volumetric-modulated arc therapy (SIB-VMAT). Methods: A total of 68 NPC patients treated by CCRT with SIB-VMAT technique were collected. QOL was longitudinally assessed by the EORTC QLQ-C30 and HN35 questionnaires at the 4 time points: baseline, 42.4 Gy (20 fractions), and 3, 12 months after CCRT. Results: The 4-year locoregional relapse free, distant metastasis free, failure free, and overall survival rates were 97.0%, 86.4%, 82.0%, and 88.1%, respectively. The 4-year cumulative incidence rate of late toxicities with grade 3 or more was 3.0%. One year after CCRT, most QOL scales, except some oral related symptoms, recovered to baseline level. Conclusion: CCRT with SIB-VMAT produces excellent locoregional control, few severe late toxicity, and good general health status for NPC patients.

KW - concurrent chemoradiotherapy

KW - nasopharyngeal carcinoma

KW - quality of life

KW - simultaneously integrated boost

KW - volumetric-modulated arc therapy

UR - http://www.scopus.com/inward/record.url?scp=85058180284&partnerID=8YFLogxK

U2 - 10.1002/hed.25551

DO - 10.1002/hed.25551

M3 - 文章

C2 - 30548091

AN - SCOPUS:85058180284

SN - 1043-3074

VL - 41

SP - 1282

EP - 1289

JO - Head and Neck

JF - Head and Neck

IS - 5

ER -

Concurrent chemoradiotherapy by simultaneously integrated boost volumetric-modulated arc therapy for nasopharyngeal carcinoma-toxicity/quality of life and survival

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this